Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs).

There was also a nonsignificant trend towards longer OS if the onset of the irAE was more than 3 months after starting ICI therapy. 86 Another study again noted improvement in ORR, DCR, median PFS, and median OS in patients who developed an irAE on ICIs.

also in 5,406 other papers